4.7 Article

IQM-PC332, a Novel DREAM Ligand with Antinociceptive Effect on Peripheral Nerve Injury-Induced Pain

Journal

Publisher

MDPI
DOI: 10.3390/ijms23042142

Keywords

DREAM; KChIP3; calsenilin; DREAM ligands; neuropathic pain; nociception; chronic constriction nerve-injury; dorsal root ganglion neuron

Ask authors/readers for more resources

Neuropathic pain is a chronic form of pain resulting from damage to neural cells. This study evaluated the analgesic effects of IQM-PC332, a new ligand that modulates ion channels, in rats with neuropathic pain. The results showed that IQM-PC332 reduced mechanical sensitivity and modulated ion currents in nerve cells, indicating its potential as a lead compound for novel analgesics.
Neuropathic pain is a form of chronic pain arising from damage of the neural cells that sense, transmit or process sensory information. Given its growing prevalence and common refractoriness to conventional analgesics, the development of new drugs with pain relief effects constitutes a prominent clinical need. In this respect, drugs that reduce activity of sensory neurons by modulating ion channels hold the promise to become effective analgesics. Here, we evaluated the mechanical antinociceptive effect of IQM-PC332, a novel ligand of the multifunctional protein downstream regulatory element antagonist modulator (DREAM) in rats subjected to chronic constriction injury of the sciatic nerve as a model of neuropathic pain. IQM-PC332 administered by intraplantar (0.01-10 mu g) or intraperitoneal (0.02-1 mu g/kg) injection reduced mechanical sensitivity by approximate to 100% of the maximum possible effect, with ED50 of 0.27 +/- 0.05 mu g and 0.09 +/- 0.01 mu g/kg, respectively. Perforated-patch whole-cell recordings in isolated dorsal root ganglion (DRG) neurons showed that IQM-PC332 (1 and 10 mu M) reduced ionic currents through voltage-gated K+ channels responsible for A-type potassium currents, low, T-type, and high voltage-activated Ca2+ channels, and transient receptor potential vanilloid-1 (TRPV1) channels. Furthermore, IQM-PC332 (1 mu M) reduced electrically evoked action potentials in DRG neurons from neuropathic animals. It is suggested that by modulating multiple DREAM-ion channel signaling complexes, IQM-PC332 may serve a lead compound of novel multimodal analgesics.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available